These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 8782016)

  • 21. [Diagnosis and virologic monitoring of HIV infection].
    Rouzioux C; Chaix ML
    Rev Prat; 1999 Oct; 49(16):1747-9. PubMed ID: 10578604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of combined zidovudine and didanosine therapy in early asymptomatic primary HIV-1 infection.
    Khajotia RR; Feigley CE; Lee E; Gu J
    AIDS; 1998 Jan; 12(2):222-4. PubMed ID: 9468376
    [No Abstract]   [Full Text] [Related]  

  • 23. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
    AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
    Vella S; Lazzarin A; Carosi G; Sinicco A; Armignacco O; Angarano G; Andreoni M; Tambussi G; Chiodera A; Floridia M; Scaccabarozzi S; Facey K; Duncan I; Boudes P; Bragman K
    Antivir Ther; 1996 Aug; 1(3):129-40. PubMed ID: 11322246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Study shows three drugs better than two.
    AIDS Alert; 1997 Apr; 12(4):39. PubMed ID: 11364145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term suppression of HIV replication in patients with sustained benefit on zidovudine monotherapy.
    Gómez-Cano M; Soriano V; Pérez-Olmeda M; Machuca A; Rodríguez-Rosado R; Valencia E; Moreno V; Gutiérrez M; González-Lahoz J
    AIDS; 1998 May; 12(8):964-6. PubMed ID: 9631158
    [No Abstract]   [Full Text] [Related]  

  • 27. HIV biological phenotype: prognosis marker for transmission, disease progression and therapy.
    Fenyö EM
    J Biol Regul Homeost Agents; 1995; 9(3):88-90. PubMed ID: 8782013
    [No Abstract]   [Full Text] [Related]  

  • 28. p24 antigenaemia as a predictor of good immunological responsiveness to zidovudine therapy in asymptomatic HIV infection.
    Montroni M; Silvestri G; Butini L; Bartocci C; Regnery C; Danieli G
    AIDS; 1992 Mar; 6(3):338-9. PubMed ID: 1567584
    [No Abstract]   [Full Text] [Related]  

  • 29. Quantitative virological measures of antiretroviral therapy.
    Katzenstein DA; Holodniy M
    AIDS Clin Rev; 1992; ():41-67. PubMed ID: 1376615
    [No Abstract]   [Full Text] [Related]  

  • 30. Transient dissociation between infectious HIV-1 titer and viral RNA during the early phase of AZT treatment.
    Zöllner B; Stellbrink HJ; Feucht HH; Schröter M; Baumgartner EM; Laufs R
    Microbiol Immunol; 1998; 42(6):471-3. PubMed ID: 9688082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation of clinical progression in human immunodeficiency virus-infected children with in vitro zidovudine resistance measured by a direct quantitative peripheral blood lymphocyte assay.
    Nielsen K; Wei LS; Sim MS; Deveikis A; Keller M; Stiehm ER; Frenkel LM; Bryson YJ
    J Infect Dis; 1995 Aug; 172(2):359-64. PubMed ID: 7622878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Viral surrogate markers: their value in the therapeutic follow-up].
    Brun-Vézinet F
    Ann Med Interne (Paris); 1993; 144(1):58-60. PubMed ID: 8503613
    [No Abstract]   [Full Text] [Related]  

  • 33. [Item 85--HIV infection: mucocutaneous manifestations of primary HIV infection].
    CEDEF
    Ann Dermatol Venereol; 2012 Oct; 139(11 Suppl):A29-31. PubMed ID: 23176857
    [No Abstract]   [Full Text] [Related]  

  • 34. Consensus statement. Scientific Advisory Committee on Surrogate Markers of HIV.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S114-6. PubMed ID: 7552508
    [No Abstract]   [Full Text] [Related]  

  • 35. Late treatment of HIV infection--is it better?
    Hamilton JD
    Infect Agents Dis; 1992 Jun; 1(3):156-62. PubMed ID: 1365540
    [No Abstract]   [Full Text] [Related]  

  • 36. [Administer zidovudine early or late?].
    Diener HC
    Med Monatsschr Pharm; 1992 Aug; 15(8):243. PubMed ID: 1508068
    [No Abstract]   [Full Text] [Related]  

  • 37. Reversibility of HIV drug resistance.
    Davenport MP
    Science; 2000 May; 288(5470):1299. PubMed ID: 10847833
    [No Abstract]   [Full Text] [Related]  

  • 38. Disease progression speeds up over time. Need for earlier treatment, follow-up.
    AIDS Alert; 2010 Nov; 25(11):123-5. PubMed ID: 21128350
    [No Abstract]   [Full Text] [Related]  

  • 39. Early zidovudine and survival in HIV infection.
    Hirschel B
    N Engl J Med; 1992 Sep; 327(11):814; author reply 815-6. PubMed ID: 1501667
    [No Abstract]   [Full Text] [Related]  

  • 40. Vancouver: optimism, but at a cost.
    Churchill D; Pym A; Coker R
    Int J STD AIDS; 1996 Oct; 7(6):385-7. PubMed ID: 8940665
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.